Metabolic dysfunction-associated steatotic liver disease is a public health threat, affecting 30% to 38% of the adult population globally. The prevalence has risen in parallel with epidemics of obesity and type 2 diabetes. In an article published in Healio News, AACE President Elect, Scott D. Isaacs, MD, FACP, FACE, discusses the importance of screening patients for MASH by identifying high-risk populations, the future of MASH treatment using combination therapies, and the need for multidisciplinary care.